Reuters USA

Walmart pushes back as major product suppliers ask for higher prices

By Siddharth Cavale and Jessica DiNapoli NEW YORK (Reuters) – Walmart Inc is warning major packaged goods makers that it can no longer stomach their price hikes, pitching its own private-label products to shoppers as less-expensive alternatives to suppliers’ name-brand goods. For the world’s biggest retailer, which reports earnings Feb. 21, any increase in prices …

Walmart pushes back as major product suppliers ask for higher prices Read More »

Ackman’s Pershing Square reaps $2.7 billion from rate trade but down 9% in 2022 -letter

By Nell Mackenzie LONDON (Reuters) – Billionaire investor William Ackman’s Pershing Square fund reaped $2.7 billion on interest rate trades in 2022, but not enough to plug losses and the fund finished the year down almost 9%, according to an investor presentation seen by Reuters. U.S. stock indexes had a dismal 2022 with the S&P …

Ackman’s Pershing Square reaps $2.7 billion from rate trade but down 9% in 2022 -letter Read More »

North American companies notch another record year for robot orders

By Timothy Aeppel (Reuters) – North American companies struggling to hire workers in the tightest labor market in decades brought on more robots last year than ever before, with many earmarked for new electric vehicle and battery factories under construction. Demand for robots appears to have slackened near the end of the year, though, raising …

North American companies notch another record year for robot orders Read More »

U.S. government to start imposing inflation penalties on drugmakers in 2025

WASHINGTON (Reuters) -The U.S. government will begin imposing penalties in 2025 on drug companies that charge its Medicare program prices that rise faster than inflation, the Centers for Medicare & Medicaid Services said on Thursday. The agency issued initial guidance on how it will implement a provision in President Joe Biden’s signature Inflation Reduction Act …

U.S. government to start imposing inflation penalties on drugmakers in 2025 Read More »